(Reuters) - Unlearn.AI, which has built a machine learning platform that creates "digital twin" profiles of patients in clinical trials, has raised $15 million to expand partnerships and accelerate ...

Unlearn's AI-generated digital twins are used in clinical trials to reduce variability, strengthen treatment effect estimation, and support go/no-go decisions-particularly in complex or hard-to-run ...

Throughout the history of medicine, drug developers have tried to make clinical trials faster and more efficient. Artificial intelligence and machine-learning methods are some of the newer approaches ...

SAN FRANCISCO--(BUSINESS WIRE)--Unlearn®, the only artificial intelligence (AI) company developing prognostic digital twins to run smaller, faster clinical trials, today announced that the European ...

The next time you sign up for a drug study, you might just gain a new twin. Unlearn.AI creates AI-powered digital twins of individual patients in order to predict how their health may change over time ...

SAN FRANCISCO--(BUSINESS WIRE)--Unlearn®, developer of the first machine-learning platform that creates Digital Twins used to populate Intelligent Control Arms in clinical studies, today announced ...

Head over to our on-demand library to view sessions from VB Transform 2023. Register Here Unlearn.ai, a company that designs software tools for clinical research, today announced that it secured $12 ...

The idea of digital twins — digital representations of humans built with computer models — for medical research is gaining traction in private and academic sectors. With predictive simulation ...

March 21 (Reuters) - Unlearn.AI, which has built a machine learning platform that creates "digital twin" profiles of patients in clinical trials, has raised $15 million to expand partnerships and ...